<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="334">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05156801</url>
  </required_header>
  <id_info>
    <org_study_id>461008P</org_study_id>
    <nct_id>NCT05156801</nct_id>
  </id_info>
  <brief_title>Efficacy of ArchSinus, NasoPore &amp; Propel to Prevent Post-Surgical MT Lateralization and Improve Symptomatic Outcomes</brief_title>
  <official_title>Efficacy of the ArchSinus, NasoPore and the Propel Stent in Preventing Post-Surgical Middle Turbinate Lateralization and Improving the Symptomatic Outcomes; Randomized, Blinded, Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>STS Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>STS Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, single-blinded comparative 3-arm clinical study. This&#xD;
      clinical study is designed to compare the efficacy of the ArchSinus stent to the Propel stent&#xD;
      (Intersect ENT), and to NasoPore (Stryker) in preventing post-FESS middle turbinate&#xD;
      lateralization 3 weeks, 6 weeks, 3 months and 12 months post FESS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      50 chronic rhinosinusitis patients, that met the inclusion criteria will undergo bilateral&#xD;
      FESS and subsequent bilateral placement of the ArchSinus into the randomized ethmoid sinus&#xD;
      cavity and NasoPore / Propel into the other ethmoid sinus cavity. Comparative treatment sides&#xD;
      will be randomly assigned; 50 sinuses treated with ArchSinus stent, 25 sinus treated with&#xD;
      Propel stent, 25 sinuses treated with Nasopore. Standard Propel implant and 4cm whole&#xD;
      NasoPore will be used.&#xD;
&#xD;
      ArchSinus stent will be removed 2 weeks (13-15 days) post FESS. Propel will be removed as&#xD;
      necessary 2 weeks (13-15 days) post FESS. NasoPore arm will be debrided as necessary 2 weeks&#xD;
      (13-15 days) post-FESS. Prior to removal / debridement procedures, the patients will be&#xD;
      blindfolded, to keep them blinded for the treatment type on each side of their nose.&#xD;
&#xD;
      All patients will be followed up at 2, 6 and 12 weeks and 12 months post FESS and examined&#xD;
      endoscopically. The endoscopic videos will be analyzed by independent pannel of 3 ENT&#xD;
      surgeons, blinded to the treatment type, to assess middle turbinate lateralization on a&#xD;
      4-point scale.&#xD;
&#xD;
      CT scan will be performed pre-FESS and 12 weeks after the operation, to assess middle&#xD;
      turbinate lateralization, as demonstrated by percent change in middle meatus (MM) area&#xD;
      pre-FESS and 12 weeks after the surgery. Inflammatory mucosal thickening will be quantified&#xD;
      using the Zinreich staging system. CT scans will be analyzed blindly by Medical Metrics Inc.&#xD;
&#xD;
      Symptomatic improvement will be analyzed weekly within 3 months follow up, using&#xD;
      Side-specific Nasal SNOT-22 questioner.&#xD;
&#xD;
      Patient symptomatic relief during the implantation time will be analyzed 2 weeks post FESS,&#xD;
      with Side-specific Nasal SNOT-22 questioner.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2022</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>50 chronic rhinosinusitis patients, that met the inclusion criteria will undergo randomization into ArchSinus / Propel or ArchSinus / NasoPore implantation group. Comparative treatment sides will be randomly assigned; 13 subjects will be assigned to ArchSinus (right)/ Propel (left); 12 subjects will be assigned to ArchSinus (left)/ Propel (right); 12 subjects will be assigned to ArchSinus (right)/ NasoPore (left); 13 subjects will be assigned to ArchSinus (left)/ NasoPore (right) groups.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Primary objective will be analyzed using nasal video endoscopy and a CT scan, by an external experts in a blinded fashion. Secondary objective will be analyzed using side-specific SNOT-22 questioner, subjects will be blinded to the treatment type.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Middle turbinate lateralization 12 week post FESS (based CT scan)</measure>
    <time_frame>12 weeks post FESS</time_frame>
    <description>The primary objective is to compare the efficacy of the ArchSinus to Propel stent (Intersect ENT), to prevent post-FESS middle turbinate lateralization, 12 weeks post-FESS, based on CT scan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Middle turbinate lateralization 12 week post FESS (based video endoscopy)</measure>
    <time_frame>12 weeks post FESS</time_frame>
    <description>The secondary objective (1) is to compare the efficacy of the ArchSinus to the Propel stent (Intersect ENT), ), to prevent post-FESS middle turbinate lateralization, 12 weeks post-FESS, based on video endoscopy on a 4-point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic outcomes within the 3-month post-FESS</measure>
    <time_frame>12 weeks post FESS</time_frame>
    <description>The secondary objective (2) is to compare the efficacy of the ArchSinus to the Propel stent (Intersect ENT) in improving the symptomatic outcomes based on side-specific SNOT-22 questioner, within the 3-month follow-up.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Re-stenosis rate 6 weeks post FESS (based video endoscopy)</measure>
    <time_frame>6 weeks post FESS</time_frame>
    <description>(1) Compare re-stenosis rate in ArchSinus / Propel / NasoPore implanted sinuses assessed on a 1 to 4 scale based on nasal endoscopy at week 6</description>
  </other_outcome>
  <other_outcome>
    <measure>symptomatic relief 2 weeks post FESS</measure>
    <time_frame>2 weeks post FESS</time_frame>
    <description>Compare symptomatic relief in ArchSinus / Propel / NasoPore implanted sinuses, based side - specific Nasal SNOT-22 score 2 weeks post-FESS.</description>
  </other_outcome>
  <other_outcome>
    <measure>Removal time</measure>
    <time_frame>2 weeks post FESS</time_frame>
    <description>Compare ArchSinus and Propel removal time</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory mucosal thickening</measure>
    <time_frame>12 weeks post FESS</time_frame>
    <description>Compare % change of inflammatory mucosal thickening 12 weeks post FESS in ArchSinus / Propel / NasoPore implanted sinuses</description>
  </other_outcome>
  <other_outcome>
    <measure>Re-stenosis rate 12 months post FESS</measure>
    <time_frame>12 months post FESS</time_frame>
    <description>Compare re-stenosis rate in ArchSinus / Propel / NasoPore implanted sinuses assessed on a 1 to 4 scale based on nasal endoscopy 12 months post FESS.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Sinusitis</condition>
  <arm_group>
    <arm_group_label>ArchSinus stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Post-FESS implantation of the study device (ArchSinus) into ethmoid sinus cavity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propel stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Post-FESS implantation of the comparator device (Propel) into ethmoid sinus cavity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NasoPore packing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Post-FESS implantation of the comparator device (NasoPore) into ethmoid sinus cavity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ArchSinus stent</intervention_name>
    <description>Post FESS unilateral placement of the ArchSinus stent into the randomized ethmoid sinus cavity.</description>
    <arm_group_label>ArchSinus stent</arm_group_label>
    <arm_group_label>NasoPore packing</arm_group_label>
    <arm_group_label>Propel stent</arm_group_label>
    <other_name>Composite Removable Sinus Stent System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of chronic rhinosinusitis defined as symptomatic inflammation of the sinuses&#xD;
             of at least 12 consecutive weeks duration despite medical management&#xD;
&#xD;
          -  CT scan examination with a minimum Zinreich score of 5 prior to study entry&#xD;
&#xD;
          -  Less than 2-point Zinreich score difference between two sides&#xD;
&#xD;
          -  Primary FESS including bilateral total ethmoidectomy; symmetrical uncinate process&#xD;
             reduction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inferior turbinectomy, reduction or outfracture&#xD;
&#xD;
          -  Polyp grade Ëƒ 4 bilaterally on Lildholdt's scale (1-3)&#xD;
&#xD;
          -  Concha bullosa&#xD;
&#xD;
          -  Severe nasal septal deviation at the level of OMC&#xD;
&#xD;
          -  Sinonasal tumors&#xD;
&#xD;
          -  FESS including asymmetrical resection of the middle turbinate&#xD;
&#xD;
          -  Known allergy to nickel&#xD;
&#xD;
          -  Known polyurethane induced dermatitis&#xD;
&#xD;
          -  Oral steroid-dependent condition&#xD;
&#xD;
          -  Momometasone furoate intolerance&#xD;
&#xD;
          -  Known hypersensitivity to lactide, glycolide or caprolactone copolymers.&#xD;
&#xD;
          -  Glaucoma or cataract&#xD;
&#xD;
          -  History of immune deficiency&#xD;
&#xD;
          -  Cystic fibrosis&#xD;
&#xD;
          -  Pregnant or lactating female&#xD;
&#xD;
          -  Acute sinus inflammation&#xD;
&#xD;
          -  Coagulation disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lena Shlossberg, MS</last_name>
    <phone>+972526826962</phone>
    <email>lena@ststent.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 29, 2021</study_first_submitted>
  <study_first_submitted_qc>December 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>December 12, 2021</last_update_submitted>
  <last_update_submitted_qc>December 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

